Patient and tissue characteristics
| Primary | Metastatic | Total | |
| Patient Number | n=26 | n=31 | n=47 |
| Gender—no. of patients (%) | |||
| Female | 13 (50) | 16 (51.6) | 29 (61.7) |
| Male | 13 (50) | 15 (48.4) | 18 (48.3) |
| Age—years | |||
| Range | 40 to 82 | 28 to 78 | 28 to 82 |
| Median | 70 | 64 | 65 |
| Primary | Metastatic (treatment-naïve) | Metastatic (on/post treatment) | |
| Biopsy site—no. of patients (%) | |||
| Tissue number | n=27 | n=29 | n=28 |
| Eye (primary tumors) | 27 (100) | ||
| Liver (metastatic tumors) | 18 (62.1) | 8 (28.6) | |
| Lung (metastatic tumors) | 6 (20.7) | 2 (10.7) | |
| Soft tissue and others (metastatic tumors) | 5 (17.2) | 17 (60.7) | |
| CD8+ cells/mm2 | |||
| Range | 0 to 992.02 | 4.16 to 1990.7 | 1.30 to 2011.9 |
| Median (SD) | 47.44 (326.09) | 361.4 (452.84) | 212.4 (530.44) |
| CD3+ cells/mm2 | |||
| Range | 1.6 to 1185.27 | 39.40 to 1371.5 | 6.73 to 3174.4 |
| Median (SD) | 87.79 (413.83) | 326.97 (397.26) | 164.2 (709.27) |
| CD68+ cells/mm2 | |||
| Range | 0 to 618.57 | 1.27 to 3604.2 | 0.63 to 2386.6 |
| Median (SD) | 81.67 (198.35) | 266.18 (763.39) | 330.06 (606.22) |
| FOXP3+ cells/mm2 | |||
| Range | 0.61 to 57.96 | 0.61 to 248.41 | 0 to 402.32 |
| Median (SD) | 8.20 (18.17) | 25.76 (71.79) | 31.07 (101.97) |
| CD4+ cells/mm2 | |||
| Range | 1.01 to 862.82 | 4.41 to 1047.91 | 5.03 to 1224.16 |
| Median (SD) | 31.91 (194.84) | 110.05 (273.70) | 87.28 (311.43) |
| PD-1+ cells/mm2 | |||
| Range | 0 to 153.18 | 0 to 276.65 | 0 to 327.89 |
| Median (SD) | 1.60 (30.17) | 3.60 (58.18) | 3.93 (82.28) |
SD, Standard deviation.